Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia Clinical research trials and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia. Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia clinical trial. Subjects frequently get the best healthcare possible for their Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.

Home > "B" Clinical Trials Conditions > Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia



Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

For Condition: accelerated phase chronic myelogenous leukemia,refractory chronic myelogenous leukemia,chronic phase chronic myelogenous leukemia
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , University of Pennsylvania Cancer Center
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients with chronic myelogenous leukemia.
Details: OBJECTIVES: I. Evaluate the ability of c-myb antisense oligodeoxynucleotide to purge bone marrow cells of clonogenic chronic myelogenous leukemia tumor cells and repopulate the bone marrow with normal stem cells in patients treated with high-dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation using marrow treated with c-myb antisense oligodeoxynucleotide. II. Determine the response rate, degree of hematopoietic reconstitution, overall survival, and relapse-free survival of these patients treated with this regimen. III. Determine the toxicity of this regimen in these patients. PROTOCOL OUTLINE: Patients undergo bone marrow harvest. The bone marrow is treated with c-myb antisense oligodeoxynucleotide and cryopreserved. A portion of the marrow is cryopreserved untreated in case of engraftment failure. Patients receive oral busulfan every 6 hours on days -7 to -4 for a total of 16 doses. Patients receive cyclophosphamide IV over 1 hour on days -3 and -2. Bone marrow is reinfused on day 0. Patients receive filgrastim (G-CSF) subcutaneously daily beginning on day 0 and continuing until blood counts recover. Patients are followed every 2-3 months for 2 years. PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 18-24 months.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/60 Years
Genders: 
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically and cytologically proven chronic myelogenous leukemia; Accelerated phase OR Chronic phase; Must have in vitro response to c-myb antisense oligodeoxynucleotide - No hypocellular marrow (less than 25% cellularity) - No patients under age 55 with a HLA-matched sibling donor --Prior/Concurrent Therapy-- - Biologic therapy: At least 3 months since prior interferon therapy - Chemotherapy: No prior busulfan - Endocrine therapy: Not specified - Radiotherapy: Not specified - Surgery: Not specified --Patient Characteristics-- - Age: 18 to 60 - Performance status: 0-1 - Hematopoietic: Granulocyte count greater than 1,000/mm3; Platelet count greater than 100,000/mm3 - Hepatic: Bilirubin less than 1.5 mg/dL; AST less than 3 times normal - Renal: Creatinine less than 2.0 mg/dL; Creatinine clearance greater than 60 mL/min - Cardiovascular: Left ventricular ejection fraction normal; No significant cardiac disease requiring digoxin, diuretics, antiarrhythmics, or antianginal medications - Pulmonary: PFTs normal with normal DLCO - Other: No persistent infection requiring antibiotics; No concurrent organ damage or medical problem that would preclude study; Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
SelinaLuger,  Study Chair,  University of Pennsylvania Cancer Center

University of Pennsylvania Cancer Center
Philadelphia,  Pennsylvania,  19104-4283
United States
 


Additional Information:
Study ID Numbers:  CDR0000063772;  UPCC-3492,NCI-H94-0532
Study Start Date: June 1993
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002592

Other Chronic Phase Chronic Myelogenous Leukemia Studies:
1. Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

2. Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia

3. Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

4. Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

5. Homoharringtonine in Treating Patients With Chronic Myelogenous Leukemia

Related Studies:

Other chronic phase chronic myelogenous leukemia Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials

Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Modify your Search

  Other chronic phase chronic myelogenous leukemia Clinical Trials
  Other Pennsylvania Clinical Trials
  Other Philadelphia Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103